pharma · No medical condition. · Generalized Myasthenia Gravis
Anaxis Pharma
Lacuna Pharma Pty Ltd
Anaxis Pharma clinical programs — 10 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- Melbourne, AU
- Founded
- 2017
- Employees
- 7
- Programs
- 10
- Drugs
- 582
- Patents
- 0
Anaxis Pharma projects
10 ClinicalTrials.gov programs sponsored by Anaxis Pharma.
Anaxis Pharma has 10 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
131I-TLX-101-003
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
CRN00808-08
Lacuna Pharma Pty Ltd
Acromegaly
1 trial -
CRN00808-09
Lacuna Pharma Pty Ltd
Acromegaly
1 trial -
CAN-201 NDG
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
EP-005
Lacuna Pharma Pty Ltd
Obesity
1 trial -
Paltusotine tablets, Paltusotine tablets
Lacuna Pharma Pty Ltd
Acromegaly
1 trial -
SNOXA12C401
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
DBP-053-01
Lacuna Pharma Pty Ltd
Glioblastoma
1 trial -
LY03010/CT-EUR-102
Lacuna Pharma Pty Ltd
Schizophrenia
1 trial -
TV44749-BA-10196
Lacuna Pharma Pty Ltd
Schizophrenia
1 trial
Frequently asked questions
How many clinical projects does Anaxis Pharma have?
10 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.